News & views
A collection of stories about our people, our research, and global health.
Browse all news
5 min read
How ‘boom and bust’ Ebola R&D funding leaves us vulnerable
We conducted a deep dive to better understand why there remains such a limited set of tools for the current Bundibugyo strain outbreak in the DRC.
5 min read
Director of External Affairs
We're hiring for a Director of External Affairs. Applications close on June 3rd.
5 min read
UK backs one in five malaria tools in development - as campaigners warn “malaria science superpower” status must be maintained
New research shows UK institutions are involved in R&D for 20% of malaria tools currently in the pipeline – the third highest of any country
-404x236.webp)
5 min read
Our Pipeline Portal: from data to decisions in global health R&D
We’re excited to introduce our new Product Pipeline portal, a single, easy-to-use tool that brings together all our data on both candidates and approved products. Learn more from Dr. Vipul Chowdhary, our Technical Lead, on how this resource can support your work.
5 min read
Compass has expanded: real-time R&D funding data now covers emerging infectious diseases and women's health
Tom Clifton shares how our Compass tool can help you spot funding trends the moment they emerge.
-404x404.webp)
10 min read
Health R&D financing in Africa: Towards resilience, innovation, and sovereignty
This brief outlines the current state of health R&D financing in Africa and underscores the importance of sustained, country-led investment amid declining global funding.
10 min read
R&D funding for neglected diseases remained stable at $4.3bn in 2024
Dr Paul Barnsley summarises the 2024 funding landscape for neglected diseases.
5 min read
The Ripple Effect 2.0: video
Key messages from The Ripple Effect 2.0 which provides quantitative, country-specific proof points showing how innovations originally developed to address health needs in low- and middle-income countries (LMICs) are now improving health outcomes and delivering economic value across the United States, United Kingdom, Japan, and Europe.
10 min read
Why global health R&D is one of the smartest investments governments can make
Céline Aerts uncovers the wide range of spillover effects that global health R&D produces in high-income countries.
